Neuroendocrine tumors originate from neuroendocrine cells, often presenting as slower-growing compared to other cancers like adenocarcinomas. Diagnosing NETs is challenging due to varied symptoms and ...

Oxford, UK, San Jose, Calif., 29 November 2023 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, ...

Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals with small cell lung cancer (SCLC) and large cell ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited ...

Two teams discover how small cell lung cancer hijacks neural pathways to proliferate faster, especially to the brain. Common ...